Literature DB >> 21183700

The prognostic value of multilineage dysplasia in de novo acute myeloid leukemia patients with intermediate-risk cytogenetics is dependent on NPM1 mutational status.

Marina Díaz-Beyá, María Rozman, Marta Pratcorona, Montserrat Torrebadell, Mireia Camós, Josep Ll Aguilar, Jordi Esteve.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21183700     DOI： 10.1182/blood-2010-09-307314

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  13 in total

1.  Reproducibility and prognostic significance of morphologic dysplasia in de novo acute myeloid leukemia.

Authors:  Olga K Weinberg; Olga Pozdnyakova; Federico Campigotto; Daniel J DeAngelo; Richard M Stone; Donna Neuberg; Robert P Hasserjian
Journal:  Mod Pathol       Date:  2015-05-15       Impact factor: 7.842

Review 2.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Authors:  Hartmut Döhner; Elihu Estey; David Grimwade; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Hervé Dombret; Benjamin L Ebert; Pierre Fenaux; Richard A Larson; Ross L Levine; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel Sanz; Jorge Sierra; Martin S Tallman; Hwei-Fang Tien; Andrew H Wei; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2016-11-28       Impact factor: 22.113

Review 3.  Acute myeloid leukaemia: optimal management and recent developments.

Authors:  Luis Villela; Javier Bolaños-Meade
Journal:  Drugs       Date:  2011-08-20       Impact factor: 9.546

4.  NPM1 mutation but not RUNX1 mutation or multilineage dysplasia defines a prognostic subgroup within de novo acute myeloid leukemia lacking recurrent cytogenetic abnormalities in the revised 2016 WHO classification.

Authors:  Olga K Weinberg; Christopher J Gibson; Traci M Blonquist; Donna Neuberg; Olga Pozdnyakova; Frank Kuo; Benjamin L Ebert; Robert P Hasserjian
Journal:  Am J Hematol       Date:  2017-05-26       Impact factor: 10.047

5.  Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AML.

Authors:  Raphael Itzykson; Thomas Cluzeau; Matthieu Duchmann; Orianne Wagner-Ballon; Thomas Boyer; Meyling Cheok; Elise Fournier; Estelle Guerin; Laurène Fenwarth; Bouchra Badaoui; Nicolas Freynet; Emmanuel Benayoun; Daniel Lusina; Isabel Garcia; Claude Gardin; Pierre Fenaux; Cécile Pautas; Bruno Quesnel; Pascal Turlure; Christine Terré; Xavier Thomas; Juliette Lambert; Aline Renneville; Claude Preudhomme; Hervé Dombret
Journal:  Leukemia       Date:  2021-10-06       Impact factor: 11.528

6.  Association of mutations with morphological dysplasia in de novo acute myeloid leukemia without 2016 WHO Classification-defined cytogenetic abnormalities.

Authors:  Olga K Weinberg; Christopher J Gibson; Traci M Blonquist; Donna Neuberg; Olga Pozdnyakova; Frank Kuo; Benjamin L Ebert; Robert P Hasserjian
Journal:  Haematologica       Date:  2018-01-11       Impact factor: 9.941

7.  Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia.

Authors:  Hassan Awada; Arda Durmaz; Carmelo Gurnari; Ashwin Kishtagari; Manja Meggendorfer; Cassandra M Kerr; Teodora Kuzmanovic; Jibran Durrani; Jacob Shreve; Yasunobu Nagata; Tomas Radivoyevitch; Anjali S Advani; Farhad Ravandi; Hetty E Carraway; Aziz Nazha; Claudia Haferlach; Yogen Saunthararajah; Jacob Scott; Valeria Visconte; Hagop Kantarjian; Tapan Kadia; Mikkael A Sekeres; Torsten Haferlach; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2021-11-11       Impact factor: 25.476

8.  Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.

Authors:  John F Seymour; Hartmut Döhner; Aleksandra Butrym; Agnieszka Wierzbowska; Dominik Selleslag; Jun Ho Jang; Rajat Kumar; James Cavenagh; Andre C Schuh; Anna Candoni; Christian Récher; Irwindeep Sandhu; Teresa Bernal Del Castillo; Haifa Kathrin Al-Ali; Jose Falantes; Richard M Stone; Mark D Minden; Jerry Weaver; Steve Songer; C L Beach; Hervé Dombret
Journal:  BMC Cancer       Date:  2017-12-14       Impact factor: 4.430

9.  ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype.

Authors:  Concepción Prats-Martín; Sergio Burillo-Sanz; Rosario M Morales-Camacho; Olga Pérez-López; Milagros Suito; Maria T Vargas; Teresa Caballero-Velázquez; Estrella Carrillo-Cruz; José González; Ricardo Bernal; José A Pérez-Simón
Journal:  Cancer Med       Date:  2020-03-26       Impact factor: 4.452

Review 10.  Diagnosis and Treatment of Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC).

Authors:  Daniel A Arber; Harry P Erba
Journal:  Am J Clin Pathol       Date:  2020-11-04       Impact factor: 2.493
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.